|  | Correlation1 | ANOVA2 |
---|---|---|---|
Variable | M ± SD (%) | r; p value | F; p value |
Group assignment | Â | -.13; 0.025 | 3.1; 0.048 |
 Standard aerobic (n = 96) | 78% ± 24% |  |  |
 Combined (n = 104) | 71% ± 23% |  |  |
 High aerobic (n = 101) | 70% ± 25% |  |  |
Location/Center | Â | .42; <0.001 | 37.8; <0.001 |
 Ottawa (n = 84) | 63% ± 27% |  |  |
 Edmonton (n = 117) | 68% ± 23% |  |  |
 Vancouver (n = 100) | 88% ± 13% |  |  |
Baseline Aerobic Exercise | Â | .14; 0.015 | 5.1; 0.024 |
 Not meeting guidelines (n = 210) | 71% ± 25% |  |  |
 Meeting guidelines (n = 91) | 78% ± 21% |  |  |
Exercise limitations | Â | -.10; 0.098 | 5.8; 0.017 |
 Not at all/a little (n = 150) | 76% ± 22% |  |  |
 Somewhat/a lot/completely (n = 151) | 70% ± 26% |  |  |
Comorbidities | Â | -.04; 0.54 | 4.0; 0.047 |
 0 (n = 135) | 76% ± 23% |  |  |
 ≥1 (n = 166) | 70% ± 24% |  |  |
Length of chemotherapy protocol | Â | -.13; 0.031 | 4.7; 0.031 |
 12 weeks (n = 89) | 78% ± 21% |  |  |
 ≥18 weeks (n = 212) | 71% ± 25% |  |  |
FEC-D3 | Â | -.14; 0.013 | 6.2; 0.013 |
 No (n = 200) | 75% ± 22% |  |  |
 Yes (n = 101) | 68% ± 27% |  |  |